Business Context and Reporting Period
This Form 8-K was filed by Theravance Biopharma, Inc. on August 15, 2025, reporting a significant corporate event under Item 8.01 Other Events. The filing details a Settlement Agreement entered into on August 15, 2025, between Theravance Biopharma subsidiaries and Mylan Ireland Limited/Viatris Specialty L.P. (collectively "Mylan") on one side, and Cipla Limited/Cipla USA, Inc. ("Cipla") on the other.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on legal and intellectual property developments regarding the product YUPELRI (revefenacin) inhalation solution.
Material Changes and Settlement Terms
- Resolution of Litigation: The agreement resolves ongoing patent litigation under the Hatch-Waxman Act initiated by Theravance and Mylan against Cipla regarding Cipla's Abbreviated New Drug Application (ANDA) for a generic version of YUPELRI.
- Patents Involved: The settlement covers twelve specific U.S. Patents owned by Theravance entities, including Nos. 8,541,451; 9,765,028; 10,550,081; 11,008,289; 11,484,531; 11,691,948; 8,017,783; 9,249,099; 10,100,013; 11,649,209; 11,858,898; 12,048,692; and 12,285,417.
- License Grant: Theravance and Mylan granted Cipla a royalty-free, non-exclusive, non-sublicensable, and non-transferable license to manufacture and market the generic YUPELRI in the United States.
- Launch Date: The licensed launch date for Cipla's generic product is set for April 23, 2039.
- Regulatory Review: The settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission as required by law.
Outlook, Risks, and Pending Matters
While the dispute with Cipla is resolved, the filing notes that patent litigation remains pending against another ANDA filer, Mankind Pharma Ltd., and certain affiliates. The primary risk associated with this filing is the regulatory approval process; the settlement is not final until reviewed and approved by the U.S. Department of Justice and the Federal Trade Commission.
Investor Verification Checklist
- Confirm the status of the U.S. Department of Justice and Federal Trade Commission review of the settlement.
- Monitor the ongoing patent litigation status against Mankind Pharma Ltd.
- Verify the specific terms and exceptions regarding the royalty-free license granted to Cipla.
- Assess the potential impact of the April 23, 2039 launch date on the long-term revenue projections for YUPELRI.